- Home
- ACI vs QGEN Comparison
ACI vs QGEN Comparison
Compare ACI & QGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACI
- QGEN
- Stock Information
- Founded
- ACI 1860
- QGEN 1986
- Country
- ACI United States
- QGEN Netherlands
- Employees
- ACI 285000
- QGEN N/A
- Industry
- ACI Food Chains
- QGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ACI Consumer Staples
- QGEN Health Care
- Exchange
- ACI Nasdaq
- QGEN Nasdaq
- Market Cap
- ACI 10.8B
- QGEN 10.3B
- IPO Year
- ACI 2020
- QGEN 1996
- Fundamental
- Price
- ACI $19.47
- QGEN $46.50
- Analyst Decision
- ACI Strong Buy
- QGEN Buy
- Analyst Count
- ACI 14
- QGEN 8
- Target Price
- ACI $24.79
- QGEN $51.01
- AVG Volume (30 Days)
- ACI 5.2M
- QGEN 1.5M
- Earning Date
- ACI 10-14-2025
- QGEN 08-05-2025
- Dividend Yield
- ACI 3.08%
- QGEN 3.24%
- EPS Growth
- ACI N/A
- QGEN 405.09
- EPS
- ACI 1.64
- QGEN 1.69
- Revenue
- ACI $81,006,300,000.00
- QGEN $2,040,067,000.00
- Revenue This Year
- ACI $4.92
- QGEN $7.22
- Revenue Next Year
- ACI $0.67
- QGEN $5.66
- P/E Ratio
- ACI $11.87
- QGEN $27.25
- Revenue Growth
- ACI 1.96
- QGEN 5.15
- 52 Week Low
- ACI $17.00
- QGEN $37.63
- 52 Week High
- ACI $23.20
- QGEN $51.88
- Technical
- Relative Strength Index (RSI)
- ACI 45.83
- QGEN 35.70
- Support Level
- ACI $19.02
- QGEN $48.68
- Resistance Level
- ACI $19.71
- QGEN $49.96
- Average True Range (ATR)
- ACI 0.30
- QGEN 0.66
- MACD
- ACI 0.07
- QGEN -0.26
- Stochastic Oscillator
- ACI 78.48
- QGEN 13.37
About ACI Albertsons Companies Inc.
Albertsons is the second-largest supermarket operator in the United States with about 2,300 stores across a variety of banners. Around 80% of the firm's sales comes from nonperishable and fresh food, of which 26% comes from its portfolio of private brands. The company operates fuel centers at about 20% of its store locations and pharmacies at 75%. Albertsons went public in 2020 following years of ownership under private equity firm Cerberus Capital Management, which still owns about a fourth of the outstanding shares.
About QGEN Qiagen N.V.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2023 sales), followed by EMEA (32%), and the Asia-Pacific (16%).